Two Biologics Work Equally Well for Active Crohn's Disease
For adults with moderate to severe Crohn's disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.
Reuters Health Information
source https://www.medscape.com/viewarticle/975660?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/975660?src=rss
Comments
Post a Comment